Strong Q4 Results and Full Year EPS Growth
Q4 revenue growth of 7.4% organically, 120 basis points of margin expansion, and adjusted diluted EPS up 11.4%. Full year EPS of $13.14, adjusted operating margin of 24.2%, and free cash flow of $3.1 billion.
Advancements in BD Medical and Interventional
In FY '24, BD Medical surpassed $1 billion in biologic drug delivery sales. BD Interventional saw strong growth with the PureWick platform and advanced tissue regeneration.
Operational Excellence and Margin Improvement
BD Excellence initiatives led to improvements in waste and operating equipment efficiency, contributing to margin expansion and cash flow above plan.
Positive Cash Flow and Capital Deployment
Free cash flow increased by 47% to $3.1 billion. Announced 53rd consecutive year of dividend increases and planned $1 billion for share repurchases over the next 12 to 18 months.